ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $639,694 | -53.6% | 93,386 | -29.8% | 0.00% | -50.0% |
| Q2 2023 | $1,379,583 | +304.1% | 133,036 | +215.3% | 0.00% | +300.0% |
| Q1 2023 | $341,398 | +126.1% | 42,200 | -54.9% | 0.00% | 0.0% |
| Q2 2020 | $151,000 | +55.7% | 93,518 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $97,000 | -96.0% | 93,518 | -92.8% | 0.00% | -87.5% |
| Q4 2019 | $2,449,000 | -39.3% | 1,295,966 | -65.3% | 0.01% | -46.7% |
| Q3 2019 | $4,034,000 | -10.5% | 3,734,793 | +81.5% | 0.02% | -6.2% |
| Q2 2019 | $4,507,000 | -36.5% | 2,057,936 | +73.6% | 0.02% | -40.7% |
| Q1 2019 | $7,101,000 | +44.2% | 1,185,528 | +77.9% | 0.03% | +22.7% |
| Q4 2018 | $4,925,000 | -15.8% | 666,430 | +65.5% | 0.02% | +4.8% |
| Q3 2018 | $5,846,000 | +260.6% | 402,624 | +396.1% | 0.02% | +200.0% |
| Q2 2018 | $1,621,000 | – | 81,166 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |